ChromaDex (NASDAQ:CDXC) Stock Price Passes Above 200 Day Moving Average of $2.47

ChromaDex Co. (NASDAQ:CDXC)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.47 and traded as high as $2.85. ChromaDex shares last traded at $2.65, with a volume of 472,368 shares.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on CDXC shares. Roth Mkm reaffirmed a “buy” rating and set a $6.00 price target on shares of ChromaDex in a research note on Wednesday, June 12th. StockNews.com started coverage on ChromaDex in a report on Sunday, March 3rd. They set a “strong-buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of ChromaDex in a report on Thursday, May 9th.

ChromaDex Stock Up 3.0 %

The stock has a market capitalization of $206.22 million, a price-to-earnings ratio of -54.60 and a beta of 1.89. The firm has a 50-day moving average of $3.16 and a two-hundred day moving average of $2.48.

ChromaDex (NASDAQ:CDXC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $22.15 million during the quarter, compared to analysts’ expectations of $22.35 million. ChromaDex had a negative return on equity of 12.61% and a negative net margin of 4.24%. As a group, sell-side analysts predict that ChromaDex Co. will post -0.02 EPS for the current year.

Hedge Funds Weigh In On ChromaDex

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tieton Capital Management LLC grew its holdings in shares of ChromaDex by 18.8% during the 4th quarter. Tieton Capital Management LLC now owns 2,913,675 shares of the company’s stock worth $4,167,000 after purchasing an additional 461,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of ChromaDex by 121.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after buying an additional 45,618 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of ChromaDex by 43.0% during the 4th quarter. International Assets Investment Management LLC now owns 28,600 shares of the company’s stock worth $410,000 after acquiring an additional 8,600 shares during the period. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of ChromaDex during the 4th quarter valued at about $118,000. Finally, Lazard Asset Management LLC bought a new stake in ChromaDex in the first quarter valued at about $43,000. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.